MCID: ADN010
MIFTS: 45

Adenosquamous Cell Lung Carcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Adenosquamous Cell Lung Carcinoma

MalaCards integrated aliases for Adenosquamous Cell Lung Carcinoma:

Name: Adenosquamous Cell Lung Carcinoma 12 14
Adenosquamous Cell Lung Cancer 69
Adenosquamous Lung Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4829
NCIt 46 C9133
UMLS 69 C0279557

Summaries for Adenosquamous Cell Lung Carcinoma

MalaCards based summary : Adenosquamous Cell Lung Carcinoma, also known as adenosquamous cell lung cancer, is related to sigmoid neoplasm and periampullary adenoma. An important gene associated with Adenosquamous Cell Lung Carcinoma is KIF5B (Kinesin Family Member 5B), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Gefitinib and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include lung and brain, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Adenosquamous Cell Lung Carcinoma

Diseases related to Adenosquamous Cell Lung Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 sigmoid neoplasm 10.5 HRAS KRAS
2 periampullary adenoma 10.4 HRAS KRAS
3 thyroid cancer, anaplastic 10.4 PIK3CA RET
4 dermatosis papulosa nigra 10.4 FGFR3 PIK3CA
5 benign struma ovarii 10.3 HRAS RET
6 apocrine adenoma 10.3 HRAS KRAS PIK3CA
7 ethmoid sinus cancer 10.3 EGFR HRAS PIK3CA
8 ethmoid sinus adenocarcinoma 10.3 EGFR HRAS PIK3CA
9 aggressive digital papillary adenocarcinoma 10.3 HRAS KRAS PIK3CA
10 breast intraductal proliferative lesion 10.3 EGFR ERBB2
11 mucinous adenocarcinoma 10.3 ALK EGFR KRAS
12 paronychia 10.3 EGFR HRAS KRAS
13 parotid gland cancer 10.3 ALK PIK3CA RET
14 intracystic papillary adenoma 10.3 EGFR ERBB2
15 pancreas adenocarcinoma 10.2 EGFR HRAS KRAS
16 colorectal adenocarcinoma 10.2 EGFR HRAS KRAS
17 progesterone-receptor negative breast cancer 10.2 EGFR ERBB2
18 bile duct cysts 10.2 HRAS KRAS
19 breast scirrhous carcinoma 10.2 EGFR ERBB2
20 cell type benign neoplasm 10.2 HRAS KRAS RET
21 adenosquamous carcinoma 10.2 EGFR KRAS PDGFRA
22 bronchiolo-alveolar adenocarcinoma 10.2 EGFR KRAS
23 struma ovarii 10.2 KRAS RET
24 multiple mucosal neuroma 10.2 ENO2 RET
25 schimmelpenning-feuerstein-mims syndrome 10.2 FGFR3 HRAS KRAS
26 malignant ectomesenchymoma 10.2 ENO2 HRAS
27 oncocytic breast carcinoma 10.1 EGFR ERBB2
28 estrogen-receptor positive breast cancer 10.1 EGFR ERBB2 PIK3CA
29 thyroid cancer, nonmedullary, 2 10.1 HRAS PIK3CA RET
30 ectomesenchymoma 10.1 ENO2 HRAS
31 small intestinal adenocarcinoma 10.1 EGFR ERBB2 KRAS
32 colonic benign neoplasm 10.1 FGFR3 HRAS KRAS
33 endometrial adenocarcinoma 10.1 EGFR ERBB2 KRAS
34 primary peritoneal carcinoma 10.1 EGFR ERBB2 RET
35 malignant peripheral nerve sheath tumor 10.1 EGFR NRG1 PDGFRA
36 duodenum cancer 10.0 ENO2 HRAS KRAS
37 liver angiosarcoma 10.0 ENO2 HRAS KRAS
38 pulmonary large cell neuroendocrine carcinoma 10.0 ENO2 ROS1
39 gallbladder cancer 10.0 EGFR ERBB2 KRAS
40 nevus, epidermal 10.0 FGFR3 HRAS KRAS PIK3CA
41 gastric leiomyosarcoma 10.0 ENO2 PDGFRA
42 uterine carcinosarcoma 10.0 EGFR ERBB2 HRAS PIK3CA
43 malignant ovarian surface epithelial-stromal neoplasm 9.9 ERBB2 HRAS KRAS PIK3CA
44 ovary epithelial cancer 9.9 ERBB2 HRAS KRAS PIK3CA
45 neurofibromatosis, type iv, of riccardi 9.9 HRAS KRAS PDGFRA RET
46 small cell carcinoma 9.9 EGFR ENO2 PDGFRA
47 exanthem 9.9 EGFR ERBB2 HRAS KRAS
48 squamous cell carcinoma, head and neck 9.9 EGFR ERBB2 HRAS PIK3CA
49 thyroid cancer 9.9 HRAS KRAS PIK3CA RET
50 pancreatic ductal adenocarcinoma 9.9 EGFR ERBB2 HRAS KRAS

Graphical network of the top 20 diseases related to Adenosquamous Cell Lung Carcinoma:



Diseases related to Adenosquamous Cell Lung Carcinoma

Symptoms & Phenotypes for Adenosquamous Cell Lung Carcinoma

GenomeRNAi Phenotypes related to Adenosquamous Cell Lung Carcinoma according to GeneCards Suite gene sharing:

25 (show top 50) (show all 60)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.17 PIK3CA EGFR HRAS KRAS
2 Decreased viability GR00106-A-0 11.17 KRAS
3 Decreased viability GR00173-A 11.17 PDGFRA
4 Decreased viability GR00221-A-1 11.17 RET ROS1 PIK3CA ARAF EGFR DDR2
5 Decreased viability GR00221-A-2 11.17 RET ROS1 PIK3CA DDR2 FGFR3 HRAS
6 Decreased viability GR00221-A-3 11.17 ERBB2 FGFR3 HRAS PDGFRA
7 Decreased viability GR00221-A-4 11.17 RET PIK3CA ARAF EGFR DDR2 ALK
8 Decreased viability GR00231-A 11.17 RET
9 Decreased viability GR00301-A 11.17 RET KRAS
10 Decreased viability GR00342-S-1 11.17 ROS1 ARAF
11 Decreased viability GR00342-S-2 11.17 ARAF
12 Decreased viability GR00342-S-3 11.17 ARAF
13 Decreased viability GR00381-A-1 11.17 KRAS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 10.25 FGFR3
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.25 PIK3CA
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.25 ERBB2
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 10.25 RET
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.25 RET
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.25 PIK3CA
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.25 RET
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.25 PIK3CA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 10.25 FGFR3
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.25 RET PIK3CA FGFR3 ERBB2
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.25 ERBB2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.21 DDR2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.21 DDR2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.21 FGFR3
28 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.21 EGFR
29 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.21 FGFR3 EGFR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.21 RET
31 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.21 RET
32 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.21 DDR2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.21 ERBB2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.21 ERBB2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.21 RET
36 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.21 ERBB2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.21 DDR2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.21 RET
39 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.21 DDR2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.21 EGFR
41 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.21 ERBB2
42 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.21 EGFR
43 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.21 EGFR
44 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.21 DDR2
45 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.21 RET
46 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.21 ERBB2
47 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.21 DDR2
48 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.21 EGFR
49 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.21 RET FGFR3
50 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.21 ERBB2 FGFR3

MGI Mouse Phenotypes related to Adenosquamous Cell Lung Carcinoma:

43 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.36 EGFR ARAF CD74 DDR2 ENO2 ALK
2 cellular MP:0005384 10.34 ROS1 EGFR CD74 ENO2 DDR2 KIF5B
3 behavior/neurological MP:0005386 10.27 ALK ARAF HRAS ERBB2 ENO2 FGFR3
4 endocrine/exocrine gland MP:0005379 10.26 EGFR ARAF DDR2 ALK KIF5B KRAS
5 mortality/aging MP:0010768 10.25 ARAF EGFR CD74 DDR2 ALK ERBB2
6 homeostasis/metabolism MP:0005376 10.24 ALK EGFR DDR2 HRAS ERBB2 KIF5B
7 craniofacial MP:0005382 10.15 EGFR ENO2 DDR2 ERBB2 HRAS FGFR3
8 digestive/alimentary MP:0005381 10.14 ARAF EGFR ERBB2 HRAS FGFR3 RET
9 integument MP:0010771 10.13 EGFR DDR2 ALK ERBB2 HRAS FGFR3
10 neoplasm MP:0002006 10.07 DDR2 ALK EGFR FGFR3 KRAS ERBB2
11 nervous system MP:0003631 10.06 ALK EGFR ENO2 DDR2 ERBB2 HRAS
12 muscle MP:0005369 10.01 ARAF EGFR DDR2 ERBB2 PIK3CA RET
13 limbs/digits/tail MP:0005371 10 EGFR DDR2 ERBB2 FGFR3 RET PDGFRA
14 no phenotypic analysis MP:0003012 9.91 EGFR DDR2 FGFR3 KRAS HRAS PDGFRA
15 reproductive system MP:0005389 9.85 ROS1 EGFR DDR2 ALK FGFR3 ERBB2
16 respiratory system MP:0005388 9.61 EGFR ENO2 ALK FGFR3 KRAS ERBB2
17 skeleton MP:0005390 9.32 EGFR CD74 DDR2 ALK HRAS FGFR3

Drugs & Therapeutics for Adenosquamous Cell Lung Carcinoma

Drugs for Adenosquamous Cell Lung Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
3
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Vinorelbine Approved, Investigational Phase 3,Phase 1 71486-22-1 44424639 60780
7
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
8
Vinblastine Approved Phase 3,Phase 1 865-21-4 241903 13342
9
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
10
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
11
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
12
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
14
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
15
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
16
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
17 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
18 Antimitotic Agents Phase 3,Phase 2,Phase 1
19 Anti-Infective Agents Phase 3,Phase 2,Phase 1
20 Antimetabolites Phase 3,Phase 2,Phase 1
21 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
22 Antiviral Agents Phase 3,Phase 2,Phase 1
23 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
24 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
25 Vitamin B Complex Phase 3,Phase 2,Phase 1
26 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
27 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
28 Mitogens Phase 3,Phase 2
29 Etoposide phosphate Phase 3,Phase 2,Phase 1
30 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
31 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
32 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
33 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
34 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
35 Analgesics Phase 3
36 Analgesics, Non-Narcotic Phase 3
37 Anti-Inflammatory Agents Phase 3
38 Anti-Inflammatory Agents, Non-Steroidal Phase 3
39 Antirheumatic Agents Phase 3
40 Cyclooxygenase 2 Inhibitors Phase 3
41 Cyclooxygenase Inhibitors Phase 3
42 Peripheral Nervous System Agents Phase 3
43 Folate Nutraceutical Phase 3,Phase 2,Phase 1
44 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
45 Shark Cartilage Nutraceutical Phase 3
46
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
47
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
48
Lenograstim Approved, Investigational Phase 2 135968-09-1
49
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
50
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860

Interventional clinical trials:

(show top 50) (show all 68)

# Name Status NCT ID Phase Drugs
1 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
2 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
3 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
4 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
5 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
6 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
7 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
8 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
9 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients Active, not recruiting NCT00030771 Phase 3 Chemotherapy
10 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
11 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
12 Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
13 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
14 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
15 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
16 Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Unknown status NCT00227708 Phase 2 docetaxel
17 Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
18 Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Unknown status NCT00033722 Phase 2 lometrexol
19 Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC Completed NCT00030810 Phase 2 Taxotere/Cisplatin
20 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
21 Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab Completed NCT00387374 Phase 2 paclitaxel;carboplatin
22 Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00454194 Phase 2 pemetrexed disodium;sorafenib tosylate
23 Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00798603 Phase 2 carboplatin;pemetrexed disodium
24 Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT01557959 Phase 2 cisplatin;erlotinib hydrochloride;docetaxel
25 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
26 Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00118183 Phase 2 docetaxel;bortezomib
27 Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
28 Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Completed NCT00010218 Phase 2 karenitecin
29 SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002642 Phase 2 cisplatin;etoposide
30 Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer Completed NCT00003202 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
31 Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00023673 Phase 1, Phase 2 carboplatin;paclitaxel
32 Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00276588 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
33 Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT01302808 Phase 1, Phase 2 erlotinib hydrochloride;romidepsin
34 Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed NCT00346320 Phase 2
35 Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00293280 Phase 2 lomustine
36 Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed NCT00550537 Phase 2 bevacizumab;carboplatin;erlotinib hydrochloride;paclitaxel
37 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00006378 Phase 2 carboplatin;paclitaxel
38 Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer Completed NCT00080938 Phase 2 Temozolomide
39 Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00077311 Phase 2 cisplatin;docetaxel;BNP7787
40 Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00025285 Phase 2 carboplatin;irinotecan hydrochloride;thalidomide
41 TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00036920 Phase 2 canfosfamide hydrochloride
42 Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer Completed NCT00006004 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride;paclitaxel
43 Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer Completed NCT00005850 Phase 2 cisplatin;fluoxetine;gemcitabine hydrochloride
44 Icotinib for Completed Resected IB NSCLC With EGFR Mutation Recruiting NCT02264210 Phase 2 Icotinib
45 Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT01059188 Phase 2 cetuximab;cisplatin;docetaxel
46 Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer Active, not recruiting NCT02186847 Phase 2 Carboplatin;Metformin Hydrochloride;Paclitaxel
47 Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer Active, not recruiting NCT00126581 Phase 2 Carboplatin;Erlotinib Hydrochloride;Paclitaxel
48 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Active, not recruiting NCT00979212 Phase 2 panitumumab;carboplatin;paclitaxel
49 Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery Active, not recruiting NCT00551369 Phase 2
50 Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer Terminated NCT00776100 Phase 2

Search NIH Clinical Center for Adenosquamous Cell Lung Carcinoma

Genetic Tests for Adenosquamous Cell Lung Carcinoma

Anatomical Context for Adenosquamous Cell Lung Carcinoma

MalaCards organs/tissues related to Adenosquamous Cell Lung Carcinoma:

38
Lung, Brain

Publications for Adenosquamous Cell Lung Carcinoma

Articles related to Adenosquamous Cell Lung Carcinoma:

# Title Authors Year
1
EGFR gene mutations in patients with adenosquamous lung carcinoma. ( 24575772 )
2014
2
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma. ( 24838432 )
2014

Variations for Adenosquamous Cell Lung Carcinoma

Cosmic variations for Adenosquamous Cell Lung Carcinoma:

9 (show top 50) (show all 78)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM95548 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 7
2 COSM95544 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 7
3 COSM95531 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 7
4 COSM95521 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 7
5 COSM95485 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 7
6 COSM95476 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 7
7 COSM96265 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64I 7
8 COSM94158 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.2691A>T p.Q897H 7
9 COSM94159 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.1555A>G p.S519G 7
10 COSM95420 TYK2 lung,NS,carcinoma,undifferentiated carcinoma c.3560G>T p.C1187F 7
11 COSM95390 TRAF5 lung,NS,carcinoma,undifferentiated carcinoma c.302G>C p.R101T 7
12 COSM10768 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.535C>T p.H179Y 7
13 COSM10742 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.578A>G p.H193R 7
14 COSM43750 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.811G>T p.E271* 7
15 COSM43753 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.560-1G>A p.? 7
16 COSM95367 TLR5 lung,NS,carcinoma,undifferentiated carcinoma c.1A>G p.M1V 7
17 COSM95359 TLR4 lung,NS,carcinoma,undifferentiated carcinoma c.337C>A p.P113T 7
18 COSM95356 TLR2 lung,NS,carcinoma,undifferentiated carcinoma c.1169A>G p.Q390R 7
19 COSM95347 TLN1 lung,NS,carcinoma,undifferentiated carcinoma c.1087C>T p.P363S 7
20 COSM95342 TLN1 lung,NS,carcinoma,undifferentiated carcinoma c.5624C>T p.S1875L 7
21 COSM95340 TLE4 lung,NS,carcinoma,undifferentiated carcinoma c.859A>C p.K287Q 7
22 COSM95334 TIAM1 lung,NS,carcinoma,undifferentiated carcinoma c.3718G>C p.E1240Q 7
23 COSM95292 STK38 lung,NS,carcinoma,undifferentiated carcinoma c.407C>G p.A136G 7
24 COSM95282 STAT1 lung,NS,carcinoma,undifferentiated carcinoma c.2042A>T p.Y681F 7
25 COSM95276 SPRY2 lung,NS,carcinoma,undifferentiated carcinoma c.652T>C p.C218R 7
26 COSM95270 SPOP lung,NS,carcinoma,undifferentiated carcinoma c.570A>C p.L190F 7
27 COSM94327 RNF145 lung,NS,carcinoma,undifferentiated carcinoma c.647G>A p.G216E 7
28 COSM95658 RIN1 lung,NS,carcinoma,undifferentiated carcinoma c.1210C>T p.Q404* 7
29 COSM95187 RICTOR lung,NS,carcinoma,undifferentiated carcinoma c.1711C>A p.H571N 7
30 COSM96136 PLCG1 lung,NS,carcinoma,undifferentiated carcinoma c.3366C>T p.D1122D 7
31 COSM95013 PKHD1 lung,NS,carcinoma,undifferentiated carcinoma c.2753C>A p.P918Q 7
32 COSM94967 PIK3C2A lung,NS,carcinoma,undifferentiated carcinoma c.3240A>T p.E1080D 7
33 COSM94958 PDIA4 lung,NS,carcinoma,undifferentiated carcinoma c.1735G>T p.V579F 7
34 COSM96110 PAX6 lung,NS,carcinoma,undifferentiated carcinoma c.372G>T p.G124G 7
35 COSM94918 PARP1 lung,NS,carcinoma,undifferentiated carcinoma c.790C>G p.L264V 7
36 COSM94897 P2RY1 lung,NS,carcinoma,undifferentiated carcinoma c.238A>G p.M80V 7
37 COSM94878 NTSR1 lung,NS,carcinoma,undifferentiated carcinoma c.808G>T p.A270S 7
38 COSM94867 NRG3 lung,NS,carcinoma,undifferentiated carcinoma c.490G>T p.A164S 7
39 COSM94848 NOTCH2 lung,NS,carcinoma,undifferentiated carcinoma c.5637G>A p.M1879I 7
40 COSM95032 MED1 lung,NS,carcinoma,undifferentiated carcinoma c.2444A>G p.H815R 7
41 COSM94685 MC5R lung,NS,carcinoma,undifferentiated carcinoma c.458T>C p.I153T 7
42 COSM94681 MAX lung,NS,carcinoma,undifferentiated carcinoma c.368A>G p.Y123C 7
43 COSM94657 MAML1 lung,NS,carcinoma,undifferentiated carcinoma c.2605C>A p.Q869K 7
44 COSM94614 LMTK2 lung,NS,carcinoma,undifferentiated carcinoma c.2931C>A p.S977R 7
45 COSM95625 LHCGR lung,NS,carcinoma,undifferentiated carcinoma c.1660C>T p.R554* 7
46 COSM520 KRAS lung,NS,carcinoma,undifferentiated carcinoma c.35G>T p.G12V 7
47 COSM516 KRAS lung,NS,carcinoma,undifferentiated carcinoma c.34G>T p.G12C 7
48 COSM95622 KIF27 lung,NS,carcinoma,undifferentiated carcinoma c.620C>G p.S207* 7
49 COSM94573 KEAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1000T>C p.Y334H 7
50 COSM94797 KAT6B lung,NS,carcinoma,undifferentiated carcinoma c.649A>G p.S217G 7

Expression for Adenosquamous Cell Lung Carcinoma

Search GEO for disease gene expression data for Adenosquamous Cell Lung Carcinoma.

Pathways for Adenosquamous Cell Lung Carcinoma

Pathways related to Adenosquamous Cell Lung Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.21 ARAF EGFR ERBB2 FGFR3 HRAS KIF5B
2
Show member pathways
14.09 ARAF CD74 EGFR ERBB2 FGFR3 HRAS
3
Show member pathways
13.9 ALK ARAF DDR2 EGFR ERBB2 FGFR3
4
Show member pathways
13.8 ALK ARAF DDR2 EGFR ERBB2 FGFR3
5
Show member pathways
13.78 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
6
Show member pathways
13.74 ALK ARAF DDR2 EGFR ERBB2 FGFR3
7
Show member pathways
13.65 ALK DDR2 EGFR ERBB2 FGFR3 HRAS
8
Show member pathways
13.58 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
9
Show member pathways
13.54 CD74 EGFR ERBB2 FGFR3 HRAS KIF5B
10
Show member pathways
13.51 ALK ARAF DDR2 EGFR ERBB2 FGFR3
11
Show member pathways
13.47 ALK DDR2 EGFR ERBB2 FGFR3 HRAS
12
Show member pathways
13.42 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
13
Show member pathways
13.38 ALK DDR2 EGFR ERBB2 FGFR3 HRAS
14
Show member pathways
13.36 EGFR ERBB2 FGFR3 HRAS KRAS NRG1
15
Show member pathways
13.27 ALK ARAF DDR2 EGFR ERBB2 FGFR3
16
Show member pathways
13.24 ARAF EGFR ERBB2 HRAS KRAS NRG1
17
Show member pathways
13.17 EGFR ERBB2 FGFR3 NRG1 PDGFRA PIK3CA
18
Show member pathways
13.15 ARAF EGFR FGFR3 HRAS KRAS NRG1
19
Show member pathways
13.15 ALK DDR2 EGFR FGFR3 HRAS KRAS
20
Show member pathways
13.1 ALK DDR2 EGFR ERBB2 FGFR3 HRAS
21
Show member pathways
13.05 EGFR FGFR3 HRAS KRAS PDGFRA PIK3CA
22
Show member pathways
13.01 ARAF EGFR ERBB2 HRAS KRAS PDGFRA
23
Show member pathways
12.99 ARAF EGFR ERBB2 HRAS KRAS PIK3CA
24
Show member pathways
12.92 EGFR HRAS KRAS PDGFRA PIK3CA
25
Show member pathways
12.86 ARAF EGFR ERBB2 HRAS KRAS PIK3CA
26 12.86 ARAF EGFR FGFR3 HRAS KRAS PDGFRA
27
Show member pathways
12.83 EGFR FGFR3 HRAS KRAS PDGFRA PIK3CA
28
Show member pathways
12.79 ERBB2 HRAS KRAS NRG1 PIK3CA
29
Show member pathways
12.78 EGFR ERBB2 FGFR3 HRAS KRAS NRG1
30
Show member pathways
12.78 ALK ARAF EGFR ERBB2 FGFR3 HRAS
31
Show member pathways
12.74 ARAF EGFR HRAS KRAS PDGFRA
32 12.72 ARAF EGFR FGFR3 HRAS KRAS PDGFRA
33
Show member pathways
12.71 EGFR ERBB2 HRAS KRAS PDGFRA PIK3CA
34
Show member pathways
12.7 ARAF EGFR ERBB2 HRAS KRAS PIK3CA
35 12.68 ALK ARAF EGFR ERBB2 FGFR3 HRAS
36 12.6 EGFR ERBB2 FGFR3 HRAS KRAS PDGFRA
37
Show member pathways
12.59 FGFR3 HRAS KRAS PIK3CA
38
Show member pathways
12.56 ARAF EGFR ERBB2 HRAS KRAS NRG1
39
Show member pathways
12.55 ARAF HRAS KRAS PIK3CA
40
Show member pathways
12.55 ARAF EGFR ERBB2 HRAS KRAS NRG1
41
Show member pathways
12.52 ERBB2 HRAS KRAS PIK3CA
42
Show member pathways
12.51 EGFR HRAS KRAS PDGFRA PIK3CA
43 12.51 EGFR FGFR3 HRAS KIF5B PDGFRA
44
Show member pathways
12.51 EGFR ERBB2 FGFR3 HRAS KRAS PDGFRA
45
Show member pathways
12.48 FGFR3 HRAS KRAS PIK3CA
46 12.48 HRAS KRAS PDGFRA PIK3CA
47
Show member pathways
12.47 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
48
Show member pathways
12.46 ARAF HRAS KRAS PIK3CA
49
Show member pathways
12.45 EGFR ERBB2 HRAS NRG1 PDGFRA PIK3CA
50
Show member pathways
12.44 EGFR HRAS PDGFRA PIK3CA

GO Terms for Adenosquamous Cell Lung Carcinoma

Cellular components related to Adenosquamous Cell Lung Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 9.8 ALK CD74 DDR2 EGFR ENO2 ERBB2
2 intracellular GO:0005622 9.7 ALK ARAF CD74 EGFR ENO2 ERBB2
3 perinuclear region of cytoplasm GO:0048471 9.65 EGFR ERBB2 HRAS KIF5B ROS1
4 plasma membrane GO:0005886 9.47 ALK CD74 DDR2 EGFR ENO2 ERBB2

Biological processes related to Adenosquamous Cell Lung Carcinoma according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 axon guidance GO:0007411 9.97 HRAS KIF5B KRAS PIK3CA RET
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 ARAF CD74 EGFR FGFR3 HRAS PDGFRA
3 leukocyte migration GO:0050900 9.94 CD74 HRAS KRAS PIK3CA
4 positive regulation of cell migration GO:0030335 9.93 EGFR HRAS PDGFRA RET
5 protein autophosphorylation GO:0046777 9.93 ALK DDR2 EGFR ERBB2 FGFR3 PDGFRA
6 positive regulation of protein phosphorylation GO:0001934 9.92 CD74 EGFR ERBB2 HRAS KRAS
7 positive regulation of protein kinase B signaling GO:0051897 9.91 EGFR ERBB2 FGFR3 NRG1 PDGFRA PIK3CA
8 wound healing GO:0042060 9.88 EGFR ERBB2 NRG1 PDGFRA
9 phosphatidylinositol phosphorylation GO:0046854 9.88 EGFR ERBB2 FGFR3 NRG1 PDGFRA PIK3CA
10 positive regulation of MAP kinase activity GO:0043406 9.85 EGFR ERBB2 HRAS KRAS
11 activation of MAPK activity GO:0000187 9.84 ALK CD74 NRG1
12 positive regulation of MAPK cascade GO:0043410 9.84 CD74 FGFR3 HRAS
13 epidermal growth factor receptor signaling pathway GO:0007173 9.84 EGFR HRAS KRAS PIK3CA
14 liver development GO:0001889 9.83 EGFR KRAS PIK3CA
15 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 ARAF EGFR PIK3CA
16 positive regulation of epithelial cell proliferation GO:0050679 9.81 EGFR ERBB2 HRAS
17 positive regulation of fibroblast proliferation GO:0048146 9.81 CD74 DDR2 EGFR PDGFRA
18 signal transduction by protein phosphorylation GO:0023014 9.8 EGFR ERBB2 ROS1
19 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.8 ALK DDR2 EGFR ERBB2 PDGFRA RET
20 positive regulation of DNA replication GO:0045740 9.79 EGFR HRAS PDGFRA
21 regulation of cell motility GO:2000145 9.77 EGFR ERBB2 NRG1
22 regulation of ERK1 and ERK2 cascade GO:0070372 9.77 EGFR ERBB2 ROS1
23 negative regulation of ERBB signaling pathway GO:1901185 9.74 EGFR ERBB2 NRG1
24 regulation of TOR signaling GO:0032006 9.67 ARAF ROS1
25 chondrocyte proliferation GO:0035988 9.66 DDR2 FGFR3
26 response to isolation stress GO:0035900 9.65 HRAS KRAS
27 endochondral bone growth GO:0003416 9.64 DDR2 FGFR3
28 ERBB2 signaling pathway GO:0038128 9.63 EGFR ERBB2 HRAS KRAS NRG1 PIK3CA
29 MAPK cascade GO:0000165 9.61 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
30 peptidyl-tyrosine phosphorylation GO:0018108 9.28 ALK DDR2 EGFR ERBB2 FGFR3 NRG1
31 signal transduction GO:0007165 10.26 ALK ARAF CD74 DDR2 EGFR ERBB2
32 phosphorylation GO:0016310 10.07 ALK ARAF DDR2 EGFR ERBB2 FGFR3
33 positive regulation of cell proliferation GO:0008284 10.04 DDR2 EGFR FGFR3 HRAS KRAS NRG1
34 cell proliferation GO:0008283 10.03 ALK CD74 EGFR ERBB2 HRAS ROS1
35 positive regulation of gene expression GO:0010628 10.02 ERBB2 HRAS KRAS NRG1 RET
36 protein phosphorylation GO:0006468 10.02 ALK ARAF DDR2 EGFR ERBB2 FGFR3

Molecular functions related to Adenosquamous Cell Lung Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.97 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
2 protein kinase activity GO:0004672 9.97 ALK ARAF DDR2 EGFR ERBB2 FGFR3
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.88 EGFR ERBB2 FGFR3 NRG1 PDGFRA RET
4 kinase activity GO:0016301 9.85 ALK ARAF DDR2 EGFR ERBB2 FGFR3
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.73 EGFR ERBB2 FGFR3 NRG1 PDGFRA PIK3CA
6 protein phosphatase binding GO:0019903 9.69 EGFR ERBB2 ROS1
7 protein tyrosine kinase activity GO:0004713 9.61 ALK DDR2 EGFR ERBB2 FGFR3 NRG1
8 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.52 EGFR ERBB2
9 ErbB-3 class receptor binding GO:0043125 9.48 ERBB2 NRG1
10 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.23 ALK DDR2 EGFR ERBB2 FGFR3 PDGFRA
11 protein binding GO:0005515 10.37 ALK ARAF CD74 DDR2 EGFR ENO2
12 ATP binding GO:0005524 10.17 ALK ARAF DDR2 EGFR ERBB2 FGFR3
13 transferase activity GO:0016740 10.16 ALK ARAF DDR2 EGFR ERBB2 FGFR3
14 identical protein binding GO:0042802 10.01 ALK CD74 EGFR ERBB2 FGFR3 KIF5B

Sources for Adenosquamous Cell Lung Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....